Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review
- 30 August 2020
- journal article
- other
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 13 (9) , 943-958
Abstract
Recent advances and drug approvals in the last decade have substantially changed the landscape of relapsed and refractory multiple myeloma (RRMM), with not only improved outcomes for patients, but ...Keywords
This publication has 77 references indexed in Scilit:
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myelomaBlood, 2015
- Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2015
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood, 2015
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myelomaHaematologica, 2015
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2015
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialThe Lancet Oncology, 2014
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with MyelomaNew England Journal of Medicine, 2014
- Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label studyBlood, 2013
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood, 2012